Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice

Journal of Hematology & Oncology

Weijing Sun¹  Gaurav Goel¹ 

[1] Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 5150 Centre Avenue, Fifth Floor, Pittsburgh 15232, PA, USA

关键词: Colorectal cancer;    Ziv-aflibercept;    Bevacizumab;    Ramucirumab;    Anti-angiogenesis;   

Others  :  1221320
DOI  :  10.1186/s13045-015-0183-8

 received in 2015-06-24, accepted in 2015-07-02,  发布年份 2015

【 摘 要 】

The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.

【 授权许可】

   
2015 Goel and Sun.

【 参考文献 】

• [1]Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R et al.. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015; 16:499-508.
• [2]Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004; 9 Suppl 1:2-10.
• [3]Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8:579-591.
• [4]Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013; 6:1. BioMed Central Full Text
• [5]Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E et al.. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14:29-37.
• [6]Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T et al.. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30:3499-3506.
• [7]Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O’Dwyer PJ et al.. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res. 2012; 18(22):6384-91.
• [8]Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC et al.. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010; 103:1407-14.
• [9]de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, Leighl N et al.. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis. 2014; 17:909-920.
• [10]Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014; 7:70. BioMed Central Full Text